Retatrutide vs Tirzepatide
Compare Retatrutide, Tirzepatide: half-life, time to Cmax, dosing interval, published dose ranges and titration — citation-backed, research use only.
| RetatrutideLY3437943View Retatrutide → | TirzepatideMounjaro, ZepboundView Tirzepatide → | |
|---|---|---|
| Class | GLP-1 | GLP-1 |
| Route | Subcutaneous | Subcutaneous |
| Plasma half-life | ~6.0 days (144 h) | ~5.0 days (120 h) |
| Time to Cmax | 36 h | 36 h |
| Typical interval | Once weekly | Once weekly |
| Published dose range | 2–12 mg | 2.5–15 mg |
| Titration ladder | 2 → 4 → 6 → 8 → 12 mg | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg |
| Summary | Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. | Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path. |
Source references
Retatrutide
- Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023)
- Rosenstock J et al., Lancet 402:529 (titration arms) (2023)
Tirzepatide
- FDA Mounjaro USPI — half-life ~5 days (120 h) (2024)
- SURPASS-2 trial — NEJM 385:503 (2021)
- Urva S et al., Clin Pharmacokinet 61:1057 (Tmax 24–72 h) (2022)
For research use only. Not for human consumption. This tracker visualises only the doses you have logged or scheduled — it does not recommend dose sizes, does not suggest what to take, and is not pharmacokinetically calibrated. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. Consult a licensed clinician before making any medical decision.